Clinical trials: Macular Telangiectasia Type 2
Macular Telangiectasia Type 2
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
- Trial name
- NCT03319849
- Testing
- NT-501
- Where
- 27 sites in United States, Australia and 1 more
- Volunteers
- 119 people
- Sponsor
- Neurotech Pharmaceuticals
MacTel (Macular Telangiectasia) Type 2
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
This was a prospective, multicenter, single-masked, sham-controlled extension study designed to provide long-term safety and efficacy follow-up data for subjects with MacTel who had NT-501 implanted intraocularly and/or underwent…
- Trial name
- NCT03071965
- Testing
- Ciliary neurotrophic factor (CNTF), Surgery
- Where
- 11 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2 (MacTel)
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
- Trial name
- NCT03316300
- Testing
- NT-501
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.
- Trial name
- NCT04729972
- Testing
- NT-501 CNTF implant
- Where
- 10 sites in United States, Australia
- Volunteers
- 33 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
Serine and Fenofibrate Study in Patients With MacTel Type 2
This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms.
- Trial name
- SAFE (NCT04907084)
- Testing
- Serine, Fenofibrate
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 89 people
- Sponsor
- The Lowy Medical Research Institute Limited